The story of the blue pill offers a complex case study for investors eyeing pharma. While first sales were explosive, present patent lapse and the rise of generic versions have severely influenced revenues. In https://kiananjfu826220.ourcodeblog.com/41425220/the-blue-pill-and-pharma-a-risky-stake